Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Cabiralizumab + Nivolumab With or Without Chemotherapy in Advanced Pancreatic Cancer
jRCT2080224088Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial of cabiralizumab and nivolumab in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Bristol Myers Squibb. Started Oct 2018; status: completed.
02
Drugs
cabiralizumabnivolumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080224088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224088.